Abstract
AL Amyloidosis is a multisystem disorder of clonal plasma cells (PCs) that produce an abnormal light chain which misfolds and deposits in organs causing cellular stress, organ dysfunction and eventually death. Available therapies target PCs to stop the production of amyloidogenic light chains. The burden of clonal PCs in bone marrow (BM) is typically less in AL than in Multiple Myeloma (MM) which is potentially advantageous for immunotherapeutic strategies. B-Cell Maturation Antigen (BCMA) is a transmembrane protein that is involved in the regulation of B cell proliferation and survival as well as maturation/differentiation into PCs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
